RxDoctor Payments Data

Thomas Brown, PA

Physician Assistant · Ithaca, NYNPI 1144323049

Payments from drug & device makers

$5,334in general payments, 2019–2025

Across 247 payments — averaging $21.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$689
  • Regeneron Healthcare Solutions, Inc.$613
  • Novartis$584
  • Sanofi$561
  • Incyte Corporation$548
  • AbbVie$502
  • plus $2K from 12 others

What the payments were for

  • Food & beverage$5,00294%
  • Education$3336%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,334 in reported general payments places this provider in the 90th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$175,125
Medicare patients
622
Services billed
3,223

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab14$139,751
Dupixent PenDupilumab28$102,776
OtezlaApremilast11$65,250
OpzeluraRuxolitinib Phosphate11$22,177
Fluorouracil56$3,529
Metronidazole34$2,526
Fluocinonide34$2,165
Clobetasol Propionate38$1,693
Ketoconazole86$1,349
Sulfacetamide Sodium13$1,172
Triamcinolone Acetonide59$717
Doxycycline Monohydrate23$620
Clindamycin Phosphate16$535
Minocycline Hcl14$290
Mupirocin27$190

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$64$65,25011 claims
Incyte CorporationOpzelura$548$22,17711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Ithaca

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →